Although aeruginascin is only present in psilocybin mushrooms and bufotenidine is present in toads, their structural and chemical similarities may be surprising.
GPCRs play a major role in the psychedelic effect. They also have qualities that make them ideal targets for drug development.
Understanding the potency of the compounds in nature’s cocktails is essential for formulating effective doses.
Severe side effects associated with 5-HT2B agonist drugs have dampened the interest of researchers. The therapeutic potential of psychedelics provides incentive for taking it up again.
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Research is revealing that the psychedelic effect is due to much more than 5-HT2A activation.
Greater potency means doing more with less. But does norpsilocin even have a role in the psychedelic effect?
This is the second crystal structure of this compound, providing additional options for developing psychedelics into therapeutic drug formulations.
Hofmann’s work with LSD started with purpose, faded away, and then went down in history.
Baeocystin does not cause the head twitch in mice, but its metabolite norpsilocin is more potent than psilocin.